Jatin Desani, MD
Hematology & Oncology · Manahaukin, NJNPI 1689868440
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $344 of the $411 with a category attached, or 83.6%. It is spread thinly across 8 manufacturers, the largest accounting for just 23.8% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $183, more than ten times the $15 reported in 2022. That places this record below the midpoint for hematology & oncology clinicians in NJ, where the typical reported total is $2,686.
Across 13 payments — averaging $31.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$98
- Intera Oncology, Inc$73
- Daiichi Sankyo Inc.$68
- GSK$60
- Johnson & Johnson$42
- E.r. Squibb & Sons, L.L.C.$37
- plus $34 from 2 others
Across 56 payments — averaging $1400.34 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Daiichi Sankyo Inc.$78K
- Merck$127
What the payments were for
- Food & beverage$34484%
- Education$6816%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 1 | $98 |
| Intera Oncology, Inc | 1 | $73 |
| Daiichi Sankyo Inc. | 3 | $68 |
| GSK | 3 | $60 |
| Johnson & Johnson | 2 | $42 |
| E.r. Squibb & Sons, L.L.C. | 1 | $37 |
| Novartis | 1 | $19 |
| Regeneron Healthcare Solutions, Inc. | 1 | $15 |
How this compares
$411 in reported general payments places this provider in the 25th percentile of 362 hematology & oncology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VenclextaVenetoclax | 28 | $341,258 |
| PomalystPomalidomide | 12 | $300,566 |
| LumakrasSotorasib | 17 | $279,489 |
| ZejulaNiraparib Tosylate | 13 | $250,577 |
| NinlaroIxazomib Citrate | 19 | $248,673 |
| AlecensaAlectinib Hcl | 18 | $237,984 |
| BosulifBosutinib | 11 | $226,477 |
| RetevmoSelpercatinib | 12 | $201,680 |
| ErleadaApalutamide | 12 | $182,528 |
| KisqaliRibociclib Succinate | 13 | $179,358 |
| XtandiEnzalutamide | 13 | $171,075 |
| NubeqaDarolutamide | 12 | $155,009 |
| TasignaNilotinib Hcl | 14 | $140,403 |
| Abiraterone Acetate | 29 | $137,653 |
| InqoviDecitabine/Cedazuridine | 15 | $119,946 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisKisqali, Tasigna | $19 | $319,76027 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $37 | $300,56612 claims |
| GSKZejula | $60 | $250,57713 claims |
| Johnson & JohnsonErleada, Xarelto | $42 | $221,84051 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 362 hematology & oncology providers in New Jersey.
Other hematology & oncology in Manahaukin
- Robert SpiegelWestfield$864K
- Amit PatelJersey City$770K
- Joshua StraussSpringfield$739K
- Charles FarberMorristown$609K
- Michael ScolaMorristown$506K
- Eshan PatelSomerville$420K
- Arturo Loaiza-BonillaPennington$406K
- Ashish ShahSpringfield$394K
- Carl HenningsonManasquan$349K
- Anthony BottiLivingston$275K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.